Mipsagargin

Drug Profile

Mipsagargin

Alternative Names: G-202; Thapsigargin prodrug

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Johns Hopkins University
  • Developer Inspyr Therapeutics; University of Texas Health Science Center at Houston
  • Class Antineoplastics; Drug conjugates; Lactones; Peptides; Sesquiterpenes
  • Mechanism of Action Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma; Hepatocellular carcinoma; Prostate cancer; Renal cell carcinoma
  • Preclinical Gastric cancer
  • No development reported Solid tumours

Most Recent Events

  • 22 Feb 2017 GenSpera withdraws prior to enrolment a phase II trial in Glioblastoma (Recurrent, Second-line therapy or greater) in USA (NCT02876003)
  • 22 Feb 2017 Preclinical trials in Gastric cancer (Combination therapy) in USA (unspecified route)
  • 22 Feb 2017 Inspyr Therapeutics plans a clinical trial for Gastric cancer (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top